Related Experiment Video
Updated: Aug 21, 2026
Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
Published on: May 2, 2022
B7-H4 enrichment represents a site-specific immunotherapy target in small bowel gastrointestinal stromal tumors
Henry Singer1, Montana Morris2, Roberta Maestro3
1Department of Surgery, Northwell Health, New Hyde Park, NY, USA.
Abstract:
Small bowel gastrointestinal stromal tumors (GISTs) are more aggressive than gastric GISTs, yet the biologic basis for this difference remains poorly understood. We hypothesized that differential expression of immune checkpoints contributes to this site-specific behavior. Bulk RNA sequencing of 42 primary GISTs (36 gastric, 6 small bowel) revealed marked upregulation of VTCN1, which encodes the inhibitory checkpoint B7-H4, in small bowel tumors (log2FC = 7.95, adjusted P < 0.001). In contrast, expression of the therapeutically targeted checkpoints PD-L1, PD-1, and CTLA-4 was comparable between sites. Concordantly, B7-H4 enrichment was accompanied by an immunosuppressive tumor microenvironment, characterized by reduced antigen-presenting cells, fewer effector-memory CD8+ T cells, lower granzyme B expression, and suppression of interferon and inflammatory signaling pathways. Notably, the differences in B7-H4 expression were independent of imatinib-treatment status. These findings were corroborated in an external cohort of 77 untreated GISTs, in which VTCN1 was similarly enriched in small bowel tumors. Independent immunohistochemical analysis of a tissue microarray comprising 68 untreated primary GISTs confirmed the pattern, showing median B7-H4 positivity of 78.6% in duodenal, 20.5% in jejunal/ileal, and 0% in gastric tumors, with staining localized to tumor cells rather than stroma. Collectively, these data identify B7-H4 as a site-specific feature of small bowel GISTs and a potential therapeutic target for tumors that have not responded to conventional checkpoint blockade.
Insights
Small bowel gastrointestinal stromal tumors (GISTs) show higher B7-H4 expression, indicating an immunosuppressive microenvironment. This immune checkpoint may be a therapeutic target for aggressive GISTs.
Area of Science:
- Oncology
- Immunology
- Gastroenterology
Background:
- Small bowel GISTs exhibit greater aggressiveness than gastric GISTs.
- The underlying biological mechanisms for this site-specific difference are not well understood.
- Immune checkpoint dysregulation is a potential contributor to GIST behavior.
Purpose of the Study:
- To investigate differential immune checkpoint expression in small bowel versus gastric GISTs.
- To identify potential molecular targets driving the aggressive nature of small bowel GISTs.
- To characterize the tumor microenvironment associated with site-specific GISTs.
Main Methods:
- Bulk RNA sequencing of 42 primary GISTs (36 gastric, 6 small bowel).
- Analysis of immune checkpoint gene expression (VTCN1, PD-L1, PD-1, CTLA-4).
- Immunohistochemical analysis of B7-H4 expression in 68 untreated GISTs.
Main Results:
- Small bowel GISTs demonstrated significant upregulation of VTCN1 (encoding B7-H4) compared to gastric GISTs.
- PD-L1, PD-1, and CTLA-4 expression levels were comparable between tumor sites.
- B7-H4 enrichment correlated with an immunosuppressive tumor microenvironment, including reduced antigen-presenting cells and effector T cells.
- B7-H4 expression differences were independent of imatinib treatment.
- Immunohistochemistry confirmed higher B7-H4 positivity in duodenal and jejunal/ileal GISTs versus gastric GISTs.
Conclusions:
- B7-H4 is a site-specific feature of small bowel GISTs, associated with an immunosuppressive tumor microenvironment.
- B7-H4 represents a potential therapeutic target for small bowel GISTs, particularly those resistant to conventional therapies.
- Understanding immune checkpoint differences can inform targeted treatment strategies for GISTs.
More Related Videos
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
06:43Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
Published on: April 3, 2026
